IVC Filters Show Mixed Outcomes in APE

Evidence synthesis highlights reduced embolism risk but persistent safety concerns and no survival benefit.

By
Andrea Surnit
April 14, 2026
4 min

Conexiant

Overview

Inferior vena cava (IVC) filters reduce the risk of subsequent pulmonary embolism (PE) in patients with venous thromboembolism but do not improve overall mortality and may increase deep vein thrombosis (DVT). Their use is recommended selectively, primarily in patients with contraindications to anticoagulation or recurrent PE despite therapy.

Background

Acute pulmonary embolism (APE) is a significant cause of morbidity and mortality despite advances in prophylaxis for deep vein thrombosis (DVT). IVC filters are designed to prevent thrombus migration from the lower extremities to the lungs and are mainly used in patients who cannot receive anticoagulation or have hemodynamically unstable APE. Clinical trials and meta-analyses have evaluated the efficacy and safety of IVC filters in reducing PE events and their impact on survival. Complications related to filter placement remain a concern, influencing guideline recommendations for their use.

Data Highlights

Study/Analysis	Findings
PREPIC Trial (400 patients)	IVC filters reduced PE occurrence but increased DVT; no significant mortality difference
PREPIC 2 Trial (399 patients)	Retrievable IVC filters plus anticoagulation did not improve outcomes over anticoagulation alone
Meta-analysis 1	IVC filters associated with 0.50 times likelihood of PE, 1.70 times likelihood of DVT; no mortality reduction
Meta-analysis 2 (1,274 patients)	Lower new PE rates at 3 months (1% vs 6%) and follow-up (3% vs 8%) with filters; no difference in DVT, bleeding, mortality
PRESERVE Study (1,421 patients)	Low rates of clinically significant PE and few adverse events over 24 months; 7% nonfatal VTE after removal
Complications	Access site bleeding (6-15%), insertion site thrombosis (2-35%), DVT (4-18%), IVC thrombosis (<10%), filter fracture (1-2%)
SAFE-IVC Study (270,866 patients)	Low retrieval rates (15-17%) but high success (94%) and low 30-day complication rates

Key Findings

IVC filters consistently reduce the incidence of subsequent pulmonary embolism but do not improve all-cause or PE-related mortality.
Use of IVC filters is associated with an increased risk of deep vein thrombosis and other complications such as filter fracture and IVC thrombosis.
Potential mortality benefit may exist in high-risk subgroups, including patients with recurrent PE despite anticoagulation and those with hemodynamically unstable APE receiving thrombolysis.
Complications from IVC filters can be frequent and increase over time, emphasizing the need for careful patient selection and monitoring.
IVC filter use has shifted toward therapeutic indications, with low retrieval rates despite high success and low complication rates upon removal.
Current guidelines recommend selective use of IVC filters in patients with contraindications to anticoagulation or recurrent venous thromboembolism and emphasize planned retrieval when possible.

Clinical Implications

Clinicians should consider IVC filter placement primarily for patients with venous thromboembolism who cannot receive anticoagulation or have recurrent PE despite adequate therapy. Given the lack of mortality benefit and the risk of complications, filters should be used selectively with structured follow-up and planned retrieval to minimize long-term adverse events. Awareness of patient-specific risk factors and close monitoring are essential to optimize outcomes.

Conclusion

IVC filters reduce pulmonary embolism incidence but do not improve survival and carry risks of complications. Their use should be reserved for carefully selected patients with contraindications to anticoagulation or recurrent PE, accompanied by planned retrieval strategies.